Tuberculosis vaccine: A journey from BCG to present

Samreen Fatima; Anjna Kumari; Gobardhan Das; Ved Prakash Dwivedi

doi:10.1016/j.lfs.2020.117594

Tuberculosis vaccine: A journey from BCG to present

Samreen Fatima, Anjna Kumari, Gobardhan Das, Ved Prakash Dwivedi

Research output: Contribution to journal › Article › peer-review

107 Scopus citations

Abstract

Tuberculosis (TB) is the leading cause of death worldwide due to an infectious disease, causing around 1.6 million deaths each year. This situation has become more complicated by the emergence of drug-resistant Mycobacterium tuberculosis (M.tb) and HIV-TB co-infection, which has significantly worsened TB prognosis and treatment. Despite years of intensive research, Bacille Calmette-Guerin (BCG) remains the only licensed vaccine and has variable efficacy. It provides protection against childhood TB but is not effective in adult pulmonary TB. As a result of intense research in understanding TB vaccinology, there are many new vaccine candidates in clinical development and many more in pre-clinical trials which aim either to replace or boost BCG vaccine. This review discusses the history of BCG vaccine development and summarizes limitations of the current vaccine strategy and recent advances in improving BCG immunization along with other new vaccines in clinical trials which are promising candidates for the future tuberculosis vaccinology program.

Original language	English (US)
Article number	117594
Journal	Life sciences
Volume	252
DOIs	https://doi.org/10.1016/j.lfs.2020.117594
State	Published - Jul 1 2020

Keywords

BCG
Cytokines
Memory cells
Mycobacterium tuberculosis
T helper cells
Vaccine

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology
Pharmacology, Toxicology and Pharmaceutics(all)

Access to Document

10.1016/j.lfs.2020.117594

Cite this

@article{aebe6028b5b04e17a1c0bbb624b69fd0,

title = "Tuberculosis vaccine: A journey from BCG to present",

abstract = "Tuberculosis (TB) is the leading cause of death worldwide due to an infectious disease, causing around 1.6 million deaths each year. This situation has become more complicated by the emergence of drug-resistant Mycobacterium tuberculosis (M.tb) and HIV-TB co-infection, which has significantly worsened TB prognosis and treatment. Despite years of intensive research, Bacille Calmette-Guerin (BCG) remains the only licensed vaccine and has variable efficacy. It provides protection against childhood TB but is not effective in adult pulmonary TB. As a result of intense research in understanding TB vaccinology, there are many new vaccine candidates in clinical development and many more in pre-clinical trials which aim either to replace or boost BCG vaccine. This review discusses the history of BCG vaccine development and summarizes limitations of the current vaccine strategy and recent advances in improving BCG immunization along with other new vaccines in clinical trials which are promising candidates for the future tuberculosis vaccinology program.",

keywords = "BCG, Cytokines, Memory cells, Mycobacterium tuberculosis, T helper cells, Vaccine",

author = "Samreen Fatima and Anjna Kumari and Gobardhan Das and Dwivedi, {Ved Prakash}",

note = "Funding Information: We acknowledge the funding support from the International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi. SF is the recipient of Senior Research Fellowship from Council of Scientific and Industrial Research (CSIR), Government of India. AK is the recipient of Junior Research Fellowship from Council of Scientific and Industrial Research (CSIR), Government of India. VPD is the recipient of DST-INSPIRE Faculty Fellowship from Department of Science and Technology, Ministry of Science and Technology , Government of India and VPD is also a recipient of Early Career Research Award from Science and Engineering Research Board (SERB), Department of Science and Technology, Ministry of Science and Technology , Government of India. Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",

year = "2020",

month = jul,

day = "1",

doi = "10.1016/j.lfs.2020.117594",

language = "English (US)",

volume = "252",

journal = "Life sciences",

issn = "0024-3205",

publisher = "Elsevier",

}

TY - JOUR

T1 - Tuberculosis vaccine

T2 - A journey from BCG to present

AU - Fatima, Samreen

AU - Kumari, Anjna

AU - Das, Gobardhan

AU - Dwivedi, Ved Prakash

N1 - Funding Information: We acknowledge the funding support from the International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi. SF is the recipient of Senior Research Fellowship from Council of Scientific and Industrial Research (CSIR), Government of India. AK is the recipient of Junior Research Fellowship from Council of Scientific and Industrial Research (CSIR), Government of India. VPD is the recipient of DST-INSPIRE Faculty Fellowship from Department of Science and Technology, Ministry of Science and Technology , Government of India and VPD is also a recipient of Early Career Research Award from Science and Engineering Research Board (SERB), Department of Science and Technology, Ministry of Science and Technology , Government of India. Publisher Copyright: © 2020 Elsevier Inc.

PY - 2020/7/1

Y1 - 2020/7/1

N2 - Tuberculosis (TB) is the leading cause of death worldwide due to an infectious disease, causing around 1.6 million deaths each year. This situation has become more complicated by the emergence of drug-resistant Mycobacterium tuberculosis (M.tb) and HIV-TB co-infection, which has significantly worsened TB prognosis and treatment. Despite years of intensive research, Bacille Calmette-Guerin (BCG) remains the only licensed vaccine and has variable efficacy. It provides protection against childhood TB but is not effective in adult pulmonary TB. As a result of intense research in understanding TB vaccinology, there are many new vaccine candidates in clinical development and many more in pre-clinical trials which aim either to replace or boost BCG vaccine. This review discusses the history of BCG vaccine development and summarizes limitations of the current vaccine strategy and recent advances in improving BCG immunization along with other new vaccines in clinical trials which are promising candidates for the future tuberculosis vaccinology program.

AB - Tuberculosis (TB) is the leading cause of death worldwide due to an infectious disease, causing around 1.6 million deaths each year. This situation has become more complicated by the emergence of drug-resistant Mycobacterium tuberculosis (M.tb) and HIV-TB co-infection, which has significantly worsened TB prognosis and treatment. Despite years of intensive research, Bacille Calmette-Guerin (BCG) remains the only licensed vaccine and has variable efficacy. It provides protection against childhood TB but is not effective in adult pulmonary TB. As a result of intense research in understanding TB vaccinology, there are many new vaccine candidates in clinical development and many more in pre-clinical trials which aim either to replace or boost BCG vaccine. This review discusses the history of BCG vaccine development and summarizes limitations of the current vaccine strategy and recent advances in improving BCG immunization along with other new vaccines in clinical trials which are promising candidates for the future tuberculosis vaccinology program.

KW - BCG

KW - Cytokines

KW - Memory cells

KW - Mycobacterium tuberculosis

KW - T helper cells

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=85084938890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85084938890&partnerID=8YFLogxK

U2 - 10.1016/j.lfs.2020.117594

DO - 10.1016/j.lfs.2020.117594

M3 - Article

C2 - 32305522

AN - SCOPUS:85084938890

SN - 0024-3205

VL - 252

JO - Life sciences

JF - Life sciences

M1 - 117594

ER -

Tuberculosis vaccine: A journey from BCG to present

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this